Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | IMPDH2 | P12268 | 19/20 | 0.72 |
| ▸ | IMPDH1 | P20839 | 16/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679270 | 1.00 | ALDH1A1 (0.73) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Hydrochloric Acid SCHEMBL9807943 | 0.99 | ALDH1A1 (0.72) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Hydrochloric Acid SCHEMBL9807935 | 0.99 | ALDH1A1 (0.72) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Sulfuric Acid SCHEMBL9807897 | 0.97 | ALDH1A1 (0.69) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| SCHEMBL9807873 | 0.91 | IMPDH2 (0.69) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| SCHEMBL9807879 | 0.91 | IMPDH2 (0.69) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Hydrochloric Acid SCHEMBL10388809 | 0.90 | IMPDH2 (0.68) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Hydrochloric Acid SCHEMBL10388808 | 0.90 | IMPDH2 (0.68) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| SCHEMBL9815242 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| SCHEMBL9815246 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0769149-B1 | IMMUNOASSAY FOR MYCOPHENOLIC ACID | DADE BEHRING MARBURG GMBH (DE) | 2005-11-09 | — | — | EP | claimed |
| US-6225073-B1 | USING MONOCLONAL ANTIBODY THAT CAN DISTINGUISH BETWEEN MYCOPHENOLIC ACID AND ITS ESTERS; FOR MONITORING BIOAVAILABILITY | DADE BEHRING MARBURG GMBH (DE) | 2001-05-01 | — | — | US | claimed |
| EP-0769149-A1 | IMMUNOASSAY FOR MYCOPHENOLIC ACID | BEHRINGWERKE AG (DE) | 1997-04-23 | — | — | EP | claimed |
| WO-1996002004-A1 | IMMUNOASSAY FOR MYCOPHENOLIC ACID | BEHRINGWERKE AG (DE) | 1996-01-25 | — | — | WO | claimed |
| US-8957071-B2 | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors | ASPREVA PHARMACEUTICALS S.A. (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20110306608-A1 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES | HAYDEN MICHAEL R (CA) | 2011-12-15 | — | — | US | disclosed |
| US-20110269755-A1 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES | Aspreva International Ltd. (CA) | 2011-11-03 | — | — | US | disclosed |
| US-20090088427-A1 | Treatment of Vascular, Autoimmune and Inflammatory Diseases Using Low Dosages of IMPDH Inhibitors | GLICKMAN RICHARD | 2009-04-02 | — | — | US | disclosed |
| US-20080280932-A1 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES | HAYDEN MICHAEL R | 2008-11-13 | — | — | US | disclosed |
| EP-1917010-A2 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES | Aspreva Pharmaceuticals SA (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20060235009-A1 | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors | ASPREVA PHARMACEUTICALS S.A. (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20060235070-A1 | Compositions and methods for treating vascular, autoimmune, and inflammatory diseases | HAYDEN MICHAEL R | 2006-10-19 | — | — | US | disclosed |
| US-4868153-A | IMMUNOSUPPRESSION | SYNTEX (U.S.A.) INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4861776-A | Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof, compositions and use | SYNTEX (U.S.A) INC. (US) | 1989-08-29 | — | — | US | disclosed |
| US-4808592-A | ANTIBODY INHIBITORS; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4786637-A | IMMUNOSUPPRESSIVE AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0281713-A1 | Morpholinoethylester of mycophenolic acid and derivatives thereof, their preparation and use in pharmaceutical compositions | SYNTEX (U.S.A.) INC. (US) | 1988-09-14 | — | — | EP | disclosed |
| US-4753935-A | ANTIBODY INHIBITORS; ANTITUMOR, ANTIINFLAMMATORY, ANTIVIRAL AND ANTIPSORIASIS AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4748173-A | IMMUNOSUPRESSIVE, ANTIINFLAMMATORY, ANTITUMOR, ANTIVIRAL, AND ANTIPSORIASIS AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-05-31 | — | — | US | disclosed |
| US-4727069-A | ANTIBODY INHIBITORS, ANTIINFLAMMATORY, ANTITUMOR AGENTS, VIRICIDES, AND ANTIPSORIATIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280932-A1 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES | IMPDH1, IMPDH2, HMGCR | ALDH1A1 563/4885LMNA 2075/4885HPGD 63/4885 |
| US-20090088427-A1 | Treatment of Vascular, Autoimmune and Inflammatory Diseases Using Low Dosages of IMPDH Inhibitors | IMPDH1, IMPDH2, PNP | ALDH1A1 87/4885LMNA 4403/4885HPGD 118/4885 |
| US-20060235070-A1 | Compositions and methods for treating vascular, autoimmune, and inflammatory diseases | IMPDH1, IMPDH2, HMGCR | ALDH1A1 563/4885LMNA 2075/4885HPGD 63/4885 |
| US-20060235009-A1 | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors | IMPDH1, IMPDH2, PNP | ALDH1A1 87/4885LMNA 4403/4885HPGD 118/4885 |
| US-20110269755-A1 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES | IMPDH1, IMPDH2, HMGCR | ALDH1A1 584/4885LMNA 2223/4885HPGD 58/4885 |
| US-20110306608-A1 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES | IMPDH1, IMPDH2, HMGCR | ALDH1A1 653/4885LMNA 2127/4885HPGD 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.